JW Pharmaceutical Corporation

A001060

KR7001060003

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 23:00:00 23/05/2024 BST			5-day change	1st Jan Change
29,050 ^KRW	-1.53%		-5.53%	-18.28%

03-14	JW Pharmaceutical Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	CI
01-22	CJ Logistics Secures Distribution Deal for JW Pharm's Intravenous Solutions	MT

JW Pharmaceutical Corporation acquired Euvipharm Pharmaceutical Joint-Stock Company.

September 03, 2019

JW Pharmaceutical Corporation (KOSE:A001060) acquired Euvipharm Pharmaceutical Joint-Stock Company on September 4, 2019. Korea Trade-Investment Promotion Agency's M&A investment team and Ho Chi Minh Office provided support to JW Pharmaceutical throughout the contract-signing process. JW Pharmaceutical Corporation (KOSE:A001060) completed the acquisition of Euvipharm Pharmaceutical Joint-Stock Company on September 4, 2019.

Latest news about JW Pharmaceutical Corporation

JW Pharmaceutical Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	03-14	CI
CJ Logistics Secures Distribution Deal for JW Pharm's Intravenous Solutions	01-22	MT
JW Pharmaceutical Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
South Korean Shares Touch Seven-Month Low on Concerns over US Fed Rate Hikes	20/10/23	MT
JW Pharmaceutical Faces Potential Fine of Nearly 30 Billion Won for Alleged Illegal Rebates	20/10/23	MT
JW Pharmaceutical Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/08/23	CI
JW Pharmaceutical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23	CI
Celleron Therapeutics Ltd acquired Argonaut Therapeutics Limited from JW Pharmaceutical Corporation and Oxford Science Enterprises.	04/01/23	CI
JW Pharmaceutical Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	15/11/22	CI
JW Pharmaceutical to Raise $3 Million via Share Sale	20/10/22	MT
JW Pharmaceutical Corporation announced that it expects to receive KRW 9.999993492 billion in funding	19/10/22	CI
JW Pharmaceutical Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	16/08/22	CI
JW Pharmaceutical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2022	16/05/22	CI
JW Pharmaceutical Corporation Reports Earnings Results for the Full Year Ended December 31, 2021	21/03/22	CI
JW Pharmaceutical Corporation announced that it has received KRW 398.470716 million in funding	12/12/21	CI
JW Pharmaceutical Corporation announced that it expects to receive KRW 398.470716 million in funding	02/12/21	CI
JW Pharmaceutical Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	15/11/21	CI
JW Pharmaceutical Corporation(KOSE:A001060) dropped from KOSPI 200 Index	14/09/21	CI
JW Pharmaceutical Corporation announced that it has received KRW 300 million in funding	17/06/21	CI
Market Chatter: JW Pharmaceutical Gets German Health Body's Permit for Phase 2a Study of Oral Atopic Dermatitis Drug	21/04/21	MT
Market Chatter: South Korean Drugmakers Queue Up for Clearance of COVID-19 Treatments in January	04/01/21	MT
JW Pharmaceutical Corporation completed the acquisition of 50% stake in C&C Research Laboratories from Chugai Pharmaceutical Co., Ltd.	30/12/19	CI
JW Pharmaceutical Corporation agreed to acquire the remaining 50% stake in C&C Research Laboratories from Chugai Pharmaceutical Co., Ltd..	26/11/19	CI
Simcere and JW Pharmaceutical Announce Collaboration and License Agreement for Anti-Gout Drug Candidate URC-102 in China	27/09/19	CI
JW Pharmaceutical Corporation acquired Euvipharm Pharmaceutical Joint-Stock Company.	03/09/19	CI

Chart JW Pharmaceutical Corporation

Duration

Period

More charts

Company Profile

JW Pharmaceutical Corp is a Korea-based company engaged in the development and manufacture of pharmaceutical products. The Company mainly produces and sells drugs including supplying protein amino acids in blood, blood and fluid substitutes, hyperlipidemia agents, electrolyte additives, angina pectoris agents, rheumatoid arthritis drugs, perfusion fluid, prostatic hypertrophy drugs, hepatic coma drugs, and iron injections, among others. The Company also researches and develops anticancer drugs.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Ratings for JW Pharmaceutical Corporation

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

29,050 KRW

Average target price

41,667 KRW

Spread / Average Target

+43.43%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
JW PHARMACEUTICAL CORPORATION	-18.28%	496M
ELI LILLY AND COMPANY	+38.51%	727B
NOVO NORDISK A/S	+32.07%	599B
JOHNSON & JOHNSON	-6.23%	354B
MERCK & CO., INC.	+18.78%	328B
ABBVIE INC.	+1.35%	277B
ASTRAZENECA PLC	+16.00%	243B
NOVARTIS AG	+8.01%	205B
ROCHE HOLDING AG	-5.97%	203B
AMGEN INC.	+6.19%	164B

Other Pharmaceuticals